Silibin B

Silibin B is one of two diastereomers of silybin, a flavonolignan extracted from milk thistle (Silybum marianum), and exerts its primary effects through antioxidant activity and inhibition of hepatic lipid peroxidation. It modulates NF-κB signaling and CYP enzyme activity to deliver hepatoprotective, anti-inflammatory, and anticancer actions at the cellular level.

Origin & History

Silibin B is a flavonolignan diastereomer isolated from the seeds of the milk thistle plant, Silybum marianum. It is extracted using techniques like silica gel column chromatography and preparative HPLC to separate it as part of the silymarin complex.

Historical & Cultural Context

There is no historical or traditional use information available for silibin B specifically in the research dossier.

Health Benefits

• Hepatoprotective properties, as demonstrated in vitro and in vivo studies.[3] • Antioxidant activity noted in pharmacological research.[3] • Anti-inflammatory effects observed in broader silybin studies.[3] • Potential anticancer properties based on preclinical data.[3] • Neuroprotective effects indicated in animal studies.[3]

How It Works

Silibin B scavenges reactive oxygen species (ROS) and inhibits lipid peroxidation by donating hydrogen atoms from its phenolic hydroxyl groups, protecting hepatocyte membranes from oxidative damage. It suppresses NF-κB and STAT3 transcription factor activation, thereby downregulating pro-inflammatory cytokines such as TNF-α and IL-6. Additionally, silibin B inhibits cytochrome P450 enzymes (notably CYP3A4 and CYP2C9) and modulates P-glycoprotein activity, influencing drug metabolism and cellular detoxification pathways.

Scientific Research

There is no specific clinical trial data or meta-analyses available for silibin B alone. Existing research focuses on the effects of the silymarin complex or the silybin A/B mixture, with no specific PMIDs provided.

Clinical Summary

Most evidence for silibin B derives from preclinical in vitro and animal studies, where it has demonstrated dose-dependent hepatocellular protection against carbon tetrachloride and acetaminophen-induced liver injury. Human clinical trials typically use standardized silymarin or silybin-phosphatidylcholine complexes (e.g., Legalon SIL 140 mg IV) rather than isolated silibin B, limiting diastereomer-specific conclusions. A pharmacokinetic study in healthy volunteers showed that silibin B exhibits higher oral bioavailability than silibin A when formulated as a phospholipid complex, reaching measurable plasma concentrations with 360 mg silybin complex doses. Overall, the clinical evidence base is preliminary, and large randomized controlled trials isolating silibin B's effects remain lacking.

Nutritional Profile

Silibin B (also spelled Silybin B) is a flavonolignan and one of the two major diastereomers of silybin, the primary bioactive component of silymarin extracted from milk thistle (Silybum marianum). It is not a conventional food nutrient but a pharmacologically active phytochemical compound. As a pure isolated compound, it does not provide meaningful macronutrients (proteins, carbohydrates, fats) or conventional micronutrients (vitamins, minerals) in supplemental doses. Bioactive compound concentration: Silibin B typically constitutes approximately 20–30% of the silybin fraction within silymarin extract, with silymarin itself comprising roughly 1.5–3% of milk thistle seed dry weight. In standardized silymarin supplements (standardized to 70–80% silymarin), silybin (combined A+B diastereomers) may represent 30–65% of total silymarin content. Bioavailability notes: Silibin B exhibits notably poor oral bioavailability (~0.5–1% in free form) due to its hydrophilic nature, low intestinal permeability, and significant first-pass metabolism. It undergoes extensive Phase II conjugation (glucuronidation and sulfation) in intestinal and hepatic tissue. Phospholipid complexes (e.g., silybin-phosphatidylcholine phytosome formulations) have been shown to increase bioavailability by 4–10 fold compared to free silybin. Plasma half-life is approximately 6–8 hours. Silibin B has demonstrated slightly different pharmacokinetic behavior compared to its diastereomer Silibin A, with some studies suggesting differential hepatic uptake and metabolic processing between the two forms.

Preparation & Dosage

No clinically studied dosage ranges for silibin B specifically are available. Silibinin (A/B mixture) dosing is not standardized. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Curcumin, Resveratrol, Quercetin, Vitamin E, Green tea extract

Safety & Interactions

Silibin B is generally well tolerated at standard silymarin-equivalent doses (140–420 mg/day), with mild gastrointestinal disturbances such as nausea, bloating, and loose stools being the most commonly reported adverse effects. Due to inhibition of CYP3A4, CYP2C9, and UGT enzymes, silibin B may elevate plasma concentrations of co-administered drugs including statins, anticoagulants like warfarin, and certain chemotherapeutics, necessitating clinical monitoring. It may exhibit additive hypoglycemic effects when combined with insulin or oral antidiabetic agents, and caution is warranted in patients on immunosuppressants such as tacrolimus. Safety data in pregnancy and lactation are insufficient, and use is generally not recommended in these populations without medical supervision.